Skip to main content
OpenTrials

Clinical trial condition

HIF-2α Mutated Cancers

Explore clinical trials studying HIF-2α Mutated Cancers. Study availability and eligibility vary by location and protocol.

1 public trial 1 recruiting study
Refine in advanced search Browse all conditions

HIF-2α Mutated Cancers trial results

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075

Conditions
Abnormalities, Multiple, Adenoma, Adenoma, Islet Cell, +31 more
Locations
  • Cedars-Sinai Medical Center ( Site 0110) Los Angeles, California, United States
  • Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130) Chicago, Illinois, United States
  • Northwestern Medicine Cancer Center - Warrenville ( Site 0134) Warrenville, Illinois, United States
  • University of Iowa ( Site 0104) Iowa City, Iowa, United States
View all 84 locations
View Trial Details

Related conditions